Phase II study of Trastuzumab in combination with TS-1 and Cisplatin for patients with Human Epidermal Growth Factor Receptor type-2 (HER-2)-positive Advanced Gastric Cancer
Latest Information Update: 04 Dec 2016
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Cisplatin; Trastuzumab
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms T-SPACE
- 11 Oct 2016 Results of biomarker analysis presented at the 41st European Society for Medical Oncology Congress.
- 31 Jan 2014 According to University Hospital Medical Information Network - Japan record study status changed from recruiting to active, no longer recruiting.
- 03 Jun 2013 Planned number of patients changed from 35 to 55 as reported by University Hospital Medical Information Network - Japan record.